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The phenotype of bilateral hippocampal sclerosis and its management in ‘real life’ clinical settings  
Abstract: 
Objective: 
There is little detailed phenotypic characterisation of bilateral hippocampal sclerosis (HS). We 
therefore conducted a multicentre review of all people with pharmacoresistant epilepsy and 
bilateral HS to better determine their clinical characteristics. 
Methods: 
Databases from 11 EPIGEN centres were searched. For identified cases, clinicians reviewed the 
medical notes, imaging, EEG, video-EEG and neuropsychometric data. Data were irretrievably 
anonymised and a single database populated to capture all phenotypic information. These data 
were compared with phenotyped cases of unilateral HS from the same centres 
Results: 
In total, 96 patients with pharmacoresistant epilepsy and bilateral HS were identified (43 female, 53 
male; age range 8-80 years). 25% had experienced febrile convulsions and 27% patients had 
experienced status epilepticus. The mean number of previously tried anti-epileptic drugs was 5.3 
and the average number of currently prescribed medications was 2.9. There was a high incidence of 
cognitive and psychological difficulties. The majority of patients continued with long-term medical 
therapy alone. Sixteen patients proceeded to, or were awaiting, neurostimulation and eleven 
underwent surgical resection. One patient was rendered seizure-free post-resection, and there was 
an improvement in seizures for three other cases. 
By comparison, of 201 patients with unilateral HS, a significantly higher number (44.3%) had 
febrile convulsions and a much lower percentage had experienced status epilepticus (11.4%). 
Importantly, focal aware seizures were common in patients with unilateral HS occurring in 41.8% 
(84/201) while such seizures were less frequently observed in people with bilateral 
HS, and were never observed exclusively (p=0.002; Fisher’s exact test) 
Significance: 
The current work describes the phenotypic spectrum of people with pharmacoresistant epilepsy and 
bilateral HS, highlights salient clinical differences from patients with unilateral HS and provides a 
large platform from which to develop further studies, both epidemiological and genomic, to better 
understand etiopathogeneisis and optimal treatment regimes in this condition.  
Key words: Bilateral hippocampal sclerosis, epilepsy surgery, phenotype, seizure semiology  
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Key points: 
1. Bilateral HS is a relatively rare, but important, cause of pharmacoresistant epilepsy 
2. 25% of people with bilateral HS experienced a febrile seizure and no patient had focal aware 
seizures alone compared to 44.3% of people with unilateral HS having had a febrile seizure 
and 41.3% of unilateral HS cases having focal aware seizures 
3. 27% of patients with bilateral HS had experienced status epilepticus, not necessarily at the 
onset of seizures 
4. Patients with bilateral HS had often tried many anti-epileptic medications and had high rates 
of cognitive and psychiatric co-morbidity 
5. In this multicentre study, only a minority of patients with bilateral HS proceeded to surgical 
(palliative) resection of one hippocampus 
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The phenotype of bilateral hippocampal sclerosis and its management in ‘real life’ clinical settings  
 
Introduction: 
The most common identifiable cause of pharmacoresistant focal epilepsy in adults is hippocampal 
sclerosis (HS). In the majority, HS is unilateral and in these cases surgical resection of the affected 
hippocampus can associate with seizure freedom in up to 70% of cases 
1,2
. However, why HS seems 
to be predominantly unilateral has remained uncertain.  
It has been long appreciated that there are cases of drug-resistant focal epilepsy in whom HS is 
bilateral. For example, in 1958 Wilder Penfield identified two cases who developed profound 
memory difficulties following standard left temporal lobectomy. He hypothesised that these two 
patients had significant, but unsuspected, right hippocampal pathology such that when he resected 
the left hippocampus, the effect was similar to bilateral temporal lobectomy
3
. Penfield’s theory was 
substantiated many years later when one of his cases (patient PB) was analysed at autopsy and was 
found to have right sided hippocampal atrophy
4
. Penfield’s noble publication in which he illustrated 
unforeseen complications of his resective surgery, led Scoville to contact him and highlight the case 
of Henri Molaison (Patient HM) who had undergone bilateral temporal lobectomies and 
subsequently developed dense anterograde amnesia. Milner travelled to Connecticut to study HM 
and it quickly became evident that bilateral temporal lobectomy was contraindicated owing to the 
profound cognitive sequelae
5,6
. 
Such observations, now six decades old, draw attention to the fact that bilateral hippocampal 
pathology can pose many difficulties. The development of MRI has enabled much better detection of 
bilateral HS
7
, a condition in which seizures are perceived to be very drug resistant and surgical 
options seem potentially limited. The exact incidence of bilateral HS is unknown and there is little 
work specifically examining the phenotypic characteristics of a large cohort of patients with bilateral 
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HS with, in particular, minimal description of patients with bilateral HS who do not proceed to 
surgical treatment. To address this, we collated data across an international consortium of tertiary 
epilepsy centres (EPIGEN) to evaluate the characteristics of such patients as well as surveying 
management of patients with bilateral HS in a ‘real-world’ setting. In addition we compared our 
data from bilateral HS cases to a large collection of unilateral HS patients collated from the same 
centres. 
 
Methods: 
EPIGEN is an international consortium of tertiary referral epilepsy centres which aims to deliver 
clinically facing genomic research. All full member institutions of the EPIGEN consortium (Columbia 
University Medical Center and New York University Langone Medical Center, New York, USA; 
Beaumont Hospital, Royal College of Surgeons of Ireland, Dublin, Ireland; Duke University, Durham, 
USA; The Royal Melbourne Hospital, Melbourne, Australia; The Chinese University of Hong Kong, 
Hong Kong; Cork University Hospital, Cork, Ireland; Toronto Western Hospital, Ontario, Canada; 
Swansea University Medical School, UK; Hôpital Erasme – ULB, Bruxelles, Belgium; John Radcliffe 
Hospital,  University of Oxford, UK), searched clinically held databases for patients with bilateral HS. 
Inclusion criteria were kept deliberately broad (Supporting Table 1), with the principal criterion being 
that patients had to have evidence of bilateral mesial temporal sclerosis on an epilepsy protocol 
brain MRI, as determined by a neuroradiologist and/or epileptologist. Bilateral HS was defined as 
demonstration of significant atrophy of both hippocampi with or without increase in signal of one or 
both hippocampi. Male and female patients of any age were included as were patients with dual 
pathology detected on brain imaging. We also specified that patients had to have tried two or more 
appropriate anti-epileptic drugs (AEDs) to enable study of patients with bilateral HS and 
pharmacoresistant epilepsy.   
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Researchers at each EPIGEN Centre then performed detailed phenotypic analysis on each identified 
patient, through thorough review of medical notes/clinical databases including imaging reports, 
electroencephalogram (EEG) recordings and video-EEG data, neuropsychometric assessments, 
operation notes, histology reports and clinical outcomes. Data were entered based on the medical 
information held at the EPIGEN centre. Data on patients who were no longer under the care of an 
EPIGEN centre were collected to the point at which medical documentation at the EPIGEN centre 
ceased.  
Phenotypic data were de-identified and entered into a database with 25 principal entry fields (See 
Supporting Table 2). Researchers were encouraged to leave fields blank if there was any uncertainty 
following review. All data were then pooled and two of the authors (AS and PD) analyzed the data. 
Where any disagreements in data interpretation were identified, consensus was agreed through 
careful discussion. All data were then subject to qualitative evaluation and relevant quantitative 
analyses were performed.  
We further compared the data obtained from the cohort of people with bilateral HS to 201 
patients with unilateral HS collated from the same EPIGEN centres enabling statistical comparison 
of phenotypic characteristics between people with bilateral HS and unilateral HS.  
 
Results: 
Basic phenotypic data 
Nine centers identified patients from patient databases with sizes ranging from 116 to 5000. Two 
centers identified patients from their clinics, which see an average of 1500-2000 patients per year. 
In total, 96 patients with bilateral HS who fulfilled the inclusion criteria were identified across the 
centres (43 female, 53 male). The ethnic diversity of patients captured reflects the centres that 
contribute to EPIGEN. The majority of cases were Caucasian (72/96), 9 of Asian descent (3 Indian, 4 
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Chinese, 2 not further specified) and 4 of African heritage. Racial origin was not documented 
formally in 11 cases.  
The duration of follow-up at the EPIGEN centres ranged from 4 weeks to 58 years (mean 7.5 years). 
The age at time of data capture ranged from 8 to 80 years (mean 49.2 years; SEM 1.64) and age of 
seizure onset ranged from 0.5 to 63 years (mean 17.4 years; SEM 1.51 years). The average 
documented duration of seizures was 30.4 years, with a range of 1-79 years (SEM 1.82 years).  
Etiopathogenesis of epilepsy 
Of the 96 patients studied, 14 (14.5%) had a confirmed family history of epilepsy. However, in only 4 
(4.2%) patients was epilepsy identified in first-degree relatives and in two of these cases the epilepsy 
identified in family members was acquired (post-traumatic epilepsy, brain tumor).  
The majority of patients did not have a documented history of febrile seizures (63 patients had no 
evidence of febrile seizures; 9 not documented). In the 24 (25.0%) patients who did have febrile 
seizures, two had prolonged febrile seizures. Interestingly, 5 patients who had febrile seizures had a 
positive family history of epilepsy, although in one case the affected relative had an acquired cause 
for their epilepsy. Similarly, 4 patients who had febrile seizures had additional clearly defined 
etiologies for developing epilepsy (1 meningitis in childhood, 2 meningoencephalitis in adulthood 
and 1 had neurosurgery in childhood (burr holes) owing to presumed intracranial hemorrhage).  
We determined the likely etiology of the patient’s HS through comprehensive assessment of each 
individual case. In 61 (63.5%) patients, no cause was identified. The most common identifiable cause 
for bilateral HS was infection, principally meningoenecephalitis (Figure 1). Four patients developed 
epilepsy secondary to birth trauma and 4 after traumatic brain injury outside of the neonatal period. 
Similarly, four patients developed bilateral HS following new onset refractory status epilepticus 
(NORSE). Three patients were found to have a potentially causal auto-antibody (one voltage gated 
potassium channel (VGKC) antibody, one anti-glutamic acid decarboxylase (GAD) antibody and one 
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not further specified, and were therefore classified as autoimmune epilepsy. However, the 
proportion of cases tested for autoantibodies was low at 12 out of 94 cases (no data available for 
2 patients). This likely reflects that the cases were acquired over many decades and many patients 
would have had a diagnosis of bilateral HS made long before antibody-mediated epilepsy was 
recognised or specific antibody testing available.  
Seizure type 
In averaging all cases where a seizure frequency per month was recorded or could be derived (e.g. 
investigator recorded seizure frequency per week), the mean seizure frequency was 10.9 seizures 
per month. Seizure type was analysed in detail (Supporting Figure 2). The majority of patients had 
either focal seizures with impaired awareness and focal to bilateral tonic clonic seizures (44/96; 
45.8%). Focal impaired awareness seizures alone occurred in 23/96 (23.9%) and focal seizures with 
and without impairment of awareness and focal to bilateral tonic clonic seizures in 16/96 (16.7%). 
No patient had only focal aware seizures. Four patients were reported to have bilateral tonic clonic 
seizures alone. Most patients did not experience status epilepticus either at outset or at any point 
(64/96; 66.7%). In total 26 (27.1%) patients had a previous history of status epilepticus and in 6 cases 
information regarding episodes of status epilepticus was not recorded.  
Medication history 
Patients included in this cohort had pharmacoresistant epilepsy and many patients had tried 
multiple AEDs. Only 7 cases did not have full datasets available for previously trialled medication and 
data were complete for currently prescribed treatments. The range of number of AEDs previously 
tried was 1-15, with a mean number of previously tried AEDs being 5.32. The average number of 
currently prescribed AEDs was 2.99 (range 1-6). 
The AEDs trialled previously are illustrated in Figure 2A. The most commonly tried AED was 
carbamazepine followed by, in descending order, valproate, lamotrigine, phenytoin and 
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levetiracetam.  By contrast, levetiracetam was the most commonly prescribed current AED followed 
by, again in descending order, lamotrigine, clobazam, valproate and carbamazepine (Figure 2B). A 
wide range of other second and third line AEDs were also either tried previously or were being 
prescribed as a current medication.  In a small number of cases intravenous immunoglobulin was 
given owing to a putative autoimmune aetiology. It can be inferred that steroids may also have been 
prescribed for these patients and possibly plasma exchange. However, no definitive comments can 
be made on immunomodulation administered to patients with bilateral HS as most centres did not 
document medications beyond conventional AEDs. 
Co-morbidities 
Many patients with bilateral HS had not undergone formal neuropsychometric testing and the 
data were often based on information from clinical letters. These data, though, were poorly 
captured and formal neuropsychometric scores were only rarely provided. Nonetheless, almost 
half of the patients were reported to have some cognitive impairment. In 17/96 (17.7%) memory 
impairment was specified while an additional 26/96 or 27.1% were reported to have cognitive 
difficulties although the specific nature of those difficulties was incompletely reported (21 
intellectual difficulties and 5 non-specified cognitive impairment).  One patient was reported to 
have learning difficulties, 3/96 (3.1%) had developmental delay and 1 patient had attention deficit 
hyperactivity disorder (ADHD) (Figure 3A). In 42 of the 96 cases (43.8%) there was no evidence for 
cognitive impairment and in 6 (6.3%) cases insufficient information was recorded.  
Psychiatric co-morbidity (Figure 3B) was present in almost half of the patients (46/96, 47.9%), with 
particular representation of depression, anxiety or both. A small number (4/96, 4.2%) developed 
inter-ictal psychosis with an additional 4 patients having experienced post-ictal psychosis. Three 
patients had dissociative seizures (psychogenic non-epileptic seizures; non-epileptic attack 
disorder) and 2.1% (2/96) had misused recreational substances.   
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As well as the commonly reported cognitive and psychological co-morbidities, these patients 
experienced many other medical co-morbidities, particularly osteoporosis (6/96; 6.3%) and 
headache (5/96, 5.2%; data not shown).  
Investigations 
All patients had to have radiologically confirmed bilateral HS to be included in the study. MRI also 
revealed additional cavernomas in 3 (3.5%) patients, post-traumatic change in two (2.4%) and 
cortical dysplasia in one. 
The majority of patients were admitted for video-telemetry (85/96; 88.5%). A wide range of both 
inter-ictal and ictal EEG findings were noted (Supporting Figure 2A and B). Thirty-six (37.5%) patients 
had bi-temporal interictal discharges and 24 (25.0%) had bilateral onset to seizures. 14/36 (38.9%) 
patients with bilateral temporal interictal discharges had no reported cognitive impairments. A 
total of 22/36 (61.1%) had cognitive impairment, intellectual disability, learning disability, or 
memory impairment. For those patients with bi-temporal onset to their seizures, 18/24 (75.0%) 
had cognitive impairment, intellectual disability, learning disability, or memory impairment. Only 
6/24 (25%) patients with bilateral temporal seizure onsets had no reported cognitive impairments.  
 Eleven (11.5%) patients underwent intracranial EEG recordings and of these the seizures had 
unilateral temporal onset in 5 (1 right, 4 left), bi-temporal onset in 4, unilateral hemispheric onset in 
1, and multifocal onset in 1 (Table 1). Wada testing (sodium amobarbital) was not performed in 
many cases as the patient had already been determined to not be a candidate for surgical resection. 
In the 17 (17.7%) patients who did undergo a Wada test, a variety of findings were reported. While 
difficult to interpret in isolation, Wada testing did demonstrate left hemispheric dominance in most 
cases.  
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Surgical interventions 
A total of 18 (18.75%) patients underwent epilepsy surgery. Of the eleven patients who underwent 
intracranial EEG monitoring, 4 subsequently had a resection (anterior temporal lobectomy [ATL], 
selective amygdalohippocampectomy [SAH], or corticectomy). Seven patients had single stage 
resections (Table 1). In 6 of the temporal lobectomies, hippocampal sclerosis was confirmed on 
pathological analysis with no histopathological data available for the other 2 cases. In the patient 
who underwent corticectomy, non-specific findings were demonstrated.  
Outcomes 
Outcome to the point of the most recent appointment in the EPIGEN centre was recorded (Figure 4). 
In 23 (24.0%) cases outcome data was not recorded and one patient died. Four patients were seizure 
free on anti-epileptic medication alone (4/96; 4.2%). Of the 11 patients who underwent surgical 
resection, only 1 patient was rendered completely seizure free, and 3 (27.3% of the patients who 
had undergone resection) showed improvement in seizure frequency. 
Around a third of patients continued with medical management alone (34/96, 35.4%). There was 
also a proportion of patients who underwent, or are considering, neurostimulation therapy with 
either vagal nerve stimulation (9/96; 9.4 %), responsive neurostimulation (6/96; 6.3%) or, in one 
case, both.  
Comparison of people with bilateral HS to those with unilateral HS 
We specifically wished to delineate how specific certain key findings were to bilateral HS. We 
therefore compared our 96 patients with 201 cases of unilateral HS also obtained from 
participating EPIGEN Centres. The key phenotypic data from the patients with unilateral HS are 
highlighted in Table 2. As illustrated, patients with unilateral HS were significantly more likely to 
have experienced febrile seizures (44.3% in unilateral HS compared to 25% in bilateral HS; p 
=0.0002; Fisher’s exact test) and were less likely to have experienced status epilepticus at any 
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point in their epilepsy history (11.4% in unilateral HS versus 27.1% in bilateral HS). While the 
Fisher’s exact test suggests a highly significant difference with regards to status epilepticus, some 
caution must be applied as data on status epilepticus were not provided for over half of patients 
with unilateral HS. Also, whereas focal aware seizures were a common seizure type in patients 
with unilateral HS being found in 84 cases (41.8%), such seizures were less frequent in people with 
bilateral HS (p=0.002; Fisher’s exact test) and no patient with bilateral disease had only focal 
aware seizures. 
 
Discussion 
The current study is the largest phenotypic characterisation of bilateral HS and epilepsy to date. 
Importantly, the study collates data from multiple epilepsy centres thereby reducing bias and also 
better reflecting ‘real-life’ clinical practice across multiple countries. Previous work
8–11 
is summarised 
in Table 3 coupled with a summary of our data. 
It is long recognised that the contralateral hippocampus in patients with unilateral hippocampal 
sclerosis may have imaging changes
12–15
 or pathological features detected at post-mortem
16
. 
Moreover, volumetry, particularly with appropriate normalisation to control values has been 
shown to enhance detection of bilateral hippocampal atrophy 13,15,17 while in studies of patients 
with unilateral HS, it has been demonstrated that the contralateral hippocampus is significantly 
smaller than control hippocampus although also larger than the hippocampus ipsilateral to the 
lobectomy, potentially best described as asymmetrical HS
15
. MR techniques have been utilised to 
try and refine bilateral mesial temporal lobe epilepsy and, for example, predict surgical outcome 
in patients with bilateral hippocampal atrophy
18
. There are also some patients with bilateral HS 
who are drug responsive. Inclusion of drug responsive cases or those with hippocampal atrophy 
defined by volumetric or more sophisticated MR analysis would have increased the number of 
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people studied, but our aim was to better describe patients with pharmacoresistant epilepsy and 
clear-cut bilateral HS visible on MR imaging in a standard clinical setting. We wished to record and 
evaluate current clinical practice and to determine whether detailed phenotypic analysis might offer 
insights to improve clinical care going forwards 
Of the 96 patients we studied, the majority were Caucasian and spanned a wide age range. The 
patients in this cohort had pharmacoresistant epilepsy and most patients had: 1) a very high number 
of seizures per month, 2) previous exposure to multiple AEDs and 3) were on average taking around 
three AEDs concurrently. The pattern of drug prescription likely reflects trends in clinical practice. 
The study was a retrospective review of medical records, and some patients had very long epilepsy 
histories. It is, therefore, perhaps unsurprising that a majority of patients had been exposed to 
carbamazepine although this was not a common current prescription with levetiracetam and 
lamotrigine now being favoured.  
Intriguingly no patient with bilateral HS had only focal aware seizures and the incidence of focal 
aware seizures overall (i.e. even when considered in combination with other seizure types) was 
also significantly lower than in patients with unilateral HS. The exact reasons for this are uncertain. 
It might, for example, be that an individual seizure from a diseased hippocampus will likely cause 
impairment of awareness in the presence of an anatomically abnormal contralateral hippocampus.  
Complex febrile seizures (either prolonged convulsion, convulsion associated with unilateral 
weakness or febrile status epilepticus in childhood) associate with an increased risk of subsequently 
developing epilepsy 
19,20
.  Some studies have reported an incidence of febrile seizures of up to nearly 
50% in patients with unilateral HS
21 and our data found an incidence of febrile seizures of 44.3% in 
unilateral HS. Similarly, previous work has shown that in patients with temporal lobe epilepsy and 
a background of febrile convulsions that majority will have unilateral hippocampal atrophy17. This 
does not seem to be recapitulated in bilateral HS. As in other work
10
 a relatively smaller proportion 
of our patients with bilateral HS had a history of febrile seizures (26%) and only two cases in this 
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cohort had prolonged febrile convulsions. It was noted that 5 patients with febrile seizures also had 
a family history of epilepsy although full information about family history of epilepsy may be lacking 
as the study was a retrospective review of available data rather than prospective acquisition of 
detailed family pedigrees. Previous genome-wide association studies have suggested a possible 
association of mesial temporal lobe epilepsy in patients who have previously had febrile convulsions 
and mutations in the SCN1A gene
22
. However, in the current work those who did have a history of 
febrile seizures often also had other risk factors for developing bilateral HS, for example a 
subsequent meningoencephalitic illness. 
While chronic epilepsy, even in patients with pre-existing hippocampal malformations, does not 
necessarily result in HS
23
, it is also well recognised that prolonged status epilepticus can result in 
profound hippocampal volume loss and associate with subsequent pharmacoresistant epilepsy
24
. 
Although patients from the latter category are represented in the current cohort, for example the 3 
patients in whom NORSE was recorded as the underlying aetiology, most patients did not have a 
history of status epilepticus. The most common aetiology cited by investigators was infection and 
other work has also demonstrated that bilateral hippocampal atrophy may be more likely after a 
meningitic or encephalitic illness17. A small number of patients were demonstrated to have a 
potentially causal antibody, but this proportion may be higher in future studies as more antibodies 
implicated in the pathogenesis of epilepsy are identified and testing for such antibodies increases. 
Despite the large number of cases included here, it is not possible to define an exact aetiology for 
bilateral HS. There are features to suggest that bilateral HS is a different entity to unilateral HS, but it 
may be that bilateral hippocampal damage represents the final common pathway of a 
heterogeneous collection of rare epilepsy syndromes. Similar to the increasing recognition that 
antibody-mediated disease may contribute to refractory status epilepticus, it can be speculated that 
certain insults, perhaps particularly infection, may lead to development of bilateral HS in people with 
a genetic susceptibility to this condition 
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As would be predicted in a group of patients with pharmacoresistant epilepsy, there were high rates 
of cognitive and psychological co-morbidity. The current study reviewed available data and therefore 
only possible surgical candidates may have had detailed neuropsychometric testing. Were all 
patients to be formally tested, the rates of recorded cognitive impairment might be higher, 
particularly as in cases of unilateral HS patients may be below the 50
th
 centile in all cognitive 
domains
25
. There was also a high rate of psychopathology with over a third of patients reporting 
depression, anxiety or both. Again, one may predict higher rates of psychiatric symptomatology 
were this to be formally evaluated for all patients. 
Only 11 (11.5%) patients pr ceeded to epilepsy surgery, which is low compared to other studies that 
have specifically reviewed surgical case series of HS. In 1996, Arruda and colleagues evaluated 74 
consecutive patients with mesial temporal lobe epilepsy undergoing surgical resection. When 
measured by volumetry, 17 of these cases had bilateral hippocampal atrophy and while the 
outcomes in this group were less favourable than in unilateral HS, 61.7% had class I or II outcome 
according to Engel’s modified classification26. More recently, Vanli-Yuvaz and colleagues reviewed 
124 patients who had undergone epilepsy surgery for hippocampal sclerosis at their centre in 
Turkey
11
. In that study 93 patients had unilateral HS and 31 had bilateral HS. The authors report that 
16.1% of bilateral HS were not pharmacoresistant and that six of nine patients with bilateral HS who 
underwent unilateral temporal lobectomy were rendered seizure free
11
. Similarly in 2013 Malter and 
colleagues evaluated patients at a single centre in Germany
9
. They also identified 31 cases of 
bilateral HS and eleven of these proceeded to surgery with resection of the putatively more 
epileptogenic sclerosed hippocampus. Of those that did progress to surgery, seizure freedom rates 
at 12 and 24 months were similar to cases of unilateral HS and no patient with bilateral HS that 
underwent resection became globally amnestic. The authors did caution that results in such small 
numbers could not be more widely extrapolated. An older study evaluated 28 patients with bilateral 
independent temporal lobe seizures detected with intracranial recording of whom 15 proceeded to 
resection
27
. Ten patients were rendered seizure free and of those seven were shown to have 
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unilateral HS on imaging or a lateralised Wada result. In the five who had persistent seizures, such 
structural or functional lateralisation was not evident
27
.  
In the current study only a single patient who underwent resective epilepsy surgery became seizure 
free post-operatively. The reasons for this relatively low percentage of operated cases may be 
multifactorial including patient choice, physician choice and increasing availability of other therapies, 
particularly new AEDs and neurostimulation. Additionally, in our cohort, very few patients (17/96; 
17.7%) had clear evidence of unilateral temporal lobe epilepsy on non-invasive video-telemetry 
while 24 patients (25%) had evidence of bilateral temporal lobe seizures. This may in turn account 
for the lower number of patients proposed for invasive investigations with Wada testing being 
performed in only 17/96 (17.7%) and intracranial recording in 11 patients (11.5%).  
While the previously published surgical case series have reported good seizure outcomes
9,11
, there is 
concern that unilateral resection in patients with bilateral HS, even if the patient is rendered seizure 
free, can compromise remaining memory function
27,28
. Moreover, there is also now increased 
understanding that patients with bilateral mesial temporal lobe epilepsy can have independent 
seizure generation in each hippocampus on a cyclical basis. Studies with ambulatory 
electrocorticography recorded from Neuropace Responsive Neurostimulation devices have shown 
that seizures may arise for several weeks in one hippocampus before then switching to the other 
29,30
. 
Given that video-telemetry is typically of one to two weeks’ duration, this may artificially skew 
interpretation if all, or most, of the seizures during EEG recording happen to arise from one of the 
sclerosed hippocampi.  
At a pathological level, those patients who underwent temporal lobectomy were found to have HS 
on histopathological examination, where this was available. Interesting work has shown that in post-
mortem cases of HS there can be bilateral accumulation of tau deposits within the sclerosed 
hippocampus
31
 and bilateral dentate granule cell dispersion
16
.  The contributions that such bilateral 
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pathology may make to cognitive difficulties and/or epileptogenesis, particularly in patients in whom 
bilateral HS is detected in vivo would be worthy of further investigation. 
Although clearly limited as a retrospective review of patient notes, the current work would suggest 
that proceeding to resection in patients with bilateral HS is not that common in real life practice and 
perhaps viewed more as a palliative, rather than a curative, procedure, even in specialist centres 
that are able offer the range of epilepsy surgeries available. Moreover, the presence or absence of 
focal aware seizures might be valuable in stratifying potential epilepsy surgical candidates going 
forwards. For example, the presence of focal aware seizures might be indicative of unilateral HS 
and, perhaps more importantly, the absence of focal aware seizures in a patient without obvious 
markers of bilateral HS might be indicative of bilateral disease and consequently a poorer post-
operative prognosis. Careful delineation of seizure phenotype could therefore offer insights into 
the possibility of sub-clinical bilateral disease, just as Penfield was attuned to so many years ago.  
 
Limitations 
This study was limited to retrospective review of patient data held at the individual EPIGEN centres. 
Despite making data entry fields formulaic, there were inevitable subjective differences in the way 
individual investigators entered data into each field. While objective information was provided for 
the majority/all patients for certain fields (for example seizure type and medications), more 
subjective data fields such as cognitive and psychological difficulties were less complete thereby 
potentially limiting interpretation. A well-defined multi-centre prospective study examining patients 
with bilateral HS would seem worthwhile.  
 
 
Page 19 of 30 Epilepsia
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
 19
Conclusions 
Patients with pharmacoresistant epilepsy and bilateral HS can pose significant challenges to 
clinicians trying to ameliorate both seizures and associated co-morbidities. In the current study, 
which samples clinical practice across multiple centres in different countries, such patients are 
shown to: 1) have frequent seizures with no patient having focal aware seizures alone; 2) have a 
relatively low frequency of febrile seizures compared to unilateral HS; 3) often have no identified 
etiology to the bilateral HS and 4) do not often proceed to surgical resection.  A prospective study 
examining a large series of cases with bilateral HS, building on data presented here, would help to 
better inform etiology as, f r example, antibody testing becomes more established. Similarly, 
genomic work in a well phenotyped group of patients with bilateral HS might provide further 
distinctions from unilateral HS. Epidemiological work is also required to better determine whether a 
more aggressive or more circumspect approach is appropriate when deciding to offer unilateral 
hippocampectomy in patients with bilateral disease.  
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Etiology of bilateral HS 
None identified (63.5%)
Autoimmune encephalitis (3.1%)
Birth injury (4.2%)
Febrile seizure (9.4%)
Meningioencephalitis (10.4%)
NORSE (4.2%)
Posttraumatic (4.2%)
FIRES (1.0%)
Figure 1: Etiology of bilateral HS 
The causes of hippocampal sclerosis were identified by referring centers. In almost two thirds of patients, no clear cause was identified. 
Infective etiologies and febrile seizures were the main attributable causes with small numbers of patients developing bilateral  HS 
following birth injury,  brain trauma, putative antibody-mediated disease, new onset refractory status epilepticus (NORSE) or febrile 
infection-related epilepsy syndrome (FIRES).  
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Previously tried medications 
Figure 2:  Anti-epileptic medications taken by patients with bilateral HS 
The cohort of patients studied had severe drug  resistant epilepsy having tried an average of 5.4 medications previously  (A) and the 
mean number of currently taken medications being 2.9 (B). A wide variety of medications had been trialled, predominantly those 
recommended for treatment of focal epilepsy. 
Abbreviations: ACET (acetazolamide); CBZ (carbamazepine); CLOB (clobazam);  CLOR (clorazepate), CLNZ (clonazepam); DIAZ (diazepam); ESLI (eslicarbazepine); ETX 
(ethosuximide); FBM (felbamate); GPN (gabapentin); IVIG (intravenous immunoglobulin), LAC (lacosamide); LEV (levetiracetam); LRZ (lorazepam); LTG (lamotrigine); MID 
(midazolam); OXC (oxcarbazepine); PER (perampanel); PB (phenobarbital), PGB (pregabalin); PHT (phenytoin), PRIM (primidone); RET (retigabine); RUF (rufinamide); TIAG 
(tiagabine); TOP (topiramate); VPA (valproate); VIG (vigabatrin); ZNS(zonisamide). PWE (persons with epilepsy) 
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Cognitive and psychiatric comorbidities 
Figure 3: Comorbidity in patients with bilateral HS 
Cognitive (3A)  and psychiatric (3B) co-morbidities occurred commonly in persons with bilateral HS. Twenty-one patients had 
intellectual disability, and 17 had memory impairment.  The most common psychiatric comorbidity was depression with or without 
anxiety.  A small percentage of patients experienced psychosis and two patients had abused recreational substances 
Cognitive comorbidities 
Anxiety (9.4%)
Depression (16.7%)
Anxiety and
depression (6.3%)
Schizophrenia,
paranoia, psychosis
(4.2%)
Substance abuse
(2.1%)
NEAD (3.1%)
None (52.1%)
Psychiatric comorbidities 3B 3A 
Intellectual disability
(21.9%)
Learning disability
(1.0%)
Developmental delay
(3.1%)
Attention Deficit
Hyperactivity Disorder
(1.0%)
None (43.8%)
Unspecified cognitive
impairment (5.2%)
Memory impairment
(17.7%)
Unable to test (6.3%)
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Outcomes 
Medical management alone (35.4%)
Seizure-free on medication (4.2%)
Single stage SAH, ATL, or corticectomy (7.3%)
ICEEG, no resection (3.1%)
ICEEG, no resection, RNS implanted or
recommended (3.1%)
ICEEG, no resection, VNS implanted or
recommended (1.0%)
ICEEG, SAH or ATL (2.1%)
ICEEG, SAH or ATL, VNS implanted or
recommended (2.1%)
VNS placed or recommended (6.3%)
RNS placed or recommended (3.1%)
Not documented (24.0%)
Figure 4: Overall outcomes in patients with bilateral HS 
The majority of patients with bilateral HS persisted with medical treatment alone.  Eleven patients had resective surgery with either 
anterior temporal lobectomy (ATL), selective amygdalohippocampectomy (SAH), or corticectomy; 4 underwent prior intracranial EEG 
monitoring (ICEEG) and 7 patients had single stage resections. Seven underwent ICEEG without subsequent resection. Sixteen patients 
had undergone, or were awaiting, neurostimulation.  Four (4.2%) became seizure-free on medication alone.  
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Table 1. Clinical characteristics of patients with bilateral HS who underwent ICEEG or resective surgery 
Demographics: 
sex,  duration 
of epilepsy 
Scalp EEG ICEEG* Wada test 
Surgical 
resection 
Pathology Outcome *** 
Male, 16 years Bilateral 
independent 
temporal 
epileptiform 
discharges and 
seizure onsets 
Bilateral 
multifocal 
seizure onsets 
Not performed No N/A Not seizure 
free, RNS 
recommended 
Male, 14 years Bitemporal 
epileptiform 
discharges, left 
temporal 
seizure onsets 
Left temporal 
seizure onsets 
Performed but 
data not 
available 
No NA Not seizure 
free 
Male, 34 years Bitemporal 
epileptiform 
discharges 
Right temporal 
onset seizures 
Not performed No N/A Not seizure 
free 
Male, 21 years Left temporal 
epileptiform 
dicharges and 
left temporal 
seizure onsets 
Bilateral 
independent, 
bisynchronous 
interictal 
discharges; 
bilateral 
independent 
and 
bisynchronous 
ictal onsets 
Left language 
dominance, 
right 
hemisphere 
memory 
impairment 
No N/A Not seizure 
free, RNS 
recommended  
Female, 20 
years 
Bilateral 
temporal 
epileptiform 
discharges and 
seizure onsets 
Bitemporal  Left language 
dominance, 
intact memory 
bilaterally 
No N/A Not seizure 
free 
Female, 22 
years 
Bilateral 
independent 
temporal 
epileptiform 
discharges, 
left-sided and 
nonlateralizable 
seizure onsets 
Left temporal 
seizure onsets 
Not performed No N/A Not seizure 
free, RNS 
implanted 
Male, 20 years Left anterior-
mid temporal 
epileptiform 
discharges, left 
temporal onset 
seizures 
No Left 
hemisphere 
language 
dominance; 
memory 
scores not 
documented 
Left  selective 
hippocampectomy  
 
Moderate mesial 
temporal sclerosis 
(MTS) 
Not seizure 
free 
Female, 33 
years 
Left temporal 
epileptiform 
discharges, left 
temporal onset 
seizures** 
No None Prior right 
temporal 
lobectomy; no 
new surgical 
resection  
Not documented Not seizure 
free 
Female, 53 
years 
Not 
documented 
No “normal right 
sided Wada” 
Right temporal 
neocorticectomy  
No evidence of 
inflammation, 
tumor, or 
congenital 
malformation 
Not seizure 
free 
Male, 44 years Right 
midtemporal 
and bilateral 
independent 
frontotemporal 
epileptiform 
discharges, 
right temporal 
onset seizures 
No Performed but 
data not 
available 
Right temporal 
lobectomy 
Mesial temporal 
sclerosis 
 
Reduced but 
not seizure 
free 
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Male, 48 years Bilateral 
temporal 
epileptiform 
discharges, 
right temporal 
onset seizures 
No Left 
hemisphere 
language 
dominance, 
right 
hemisphere 
memory 
impairment 
Right selective 
amygadalo-
hippocampectomy 
with subsequent 
temporal 
lobectomy 
Hippocampal 
sclerosis 
 
Reduced but 
not seizure 
free 
Male, 63 years Bilateral 
independent 
temporal 
epileptiform 
discharges, left 
temporal and 
bitemporal 
onset seizures 
No Left 
hemisphere 
language 
dominance, 
intact memory 
bilaterally 
Left selective 
amygdalo-
hippocampectomy 
Severe 
hippocampal 
sclerosis 
Dramatically 
improved but 
not seizure 
free 
Female, 60 
years 
No interictal 
epileptiform 
abnormalities, 
left temporal 
onset seizures 
No Not performed Left temporal 
lobectomy 
Pathology not 
available 
Not seizure 
free 
Male, 22 years Left temporal 
epileptiform 
discharges, 
nonlateralizable 
seizure onsets 
Diffuse left 
hemispheric 
seizure onsets 
Not performed Prior corpus 
callosotomy; no 
new surgical 
resection 
N/A Not seizure 
free.  
Male, 13 years Bilateral 
independent 
temporal 
epileptiform 
discharges and 
seizure onsets 
Bilateral 
temporal 
seizure 
onsets, right > 
left 
Left 
hemisphere 
language 
dominance, 
bilateral 
memory 
impairment 
Right temporal 
lobectomy   
MTS; 
malformation of 
cortical 
development  
Palmini grade I 
Not seizure 
free, VNS 
implanted 
Male, 4 years Bilateral 
independent 
temporal 
epileptiform 
discharges and 
seizure onsets 
Left temporal 
seizure onsets 
Not performed Left temporal 
lobectomy  
 
Severe MTS; 
focal cortical 
dysplasia and 
microdysgenesis 
Not seizure 
free. VNS 
recommended. 
Female, 36 
years 
Left temporal 
and 
bisynchronous 
temporal 
epileptiform 
discharges; 
broad left 
hemispheric 
seizure onsets 
Left temporal 
discharges, 
left temporal 
seizure onset 
Left 
hemisphere 
language 
dominance, 
bilateral 
memory 
impairment 
Left temporal 
lobectomy 
 
 
Severe MTS; 
malformation of 
cortical 
development 
Palmini IA 
Seizure free 
Female, 23 
years 
Left temporal 
epileptiform 
discharges, 
broad left 
hemispheric 
seizure onsets 
Bilateral 
temporal 
seizure 
onsets, left > 
right  
Bilateral 
language 
dominance, 
bilateral 
memory 
dysfunction 
Left temporal 
lobectomy 
 
Severe MTS; 
malformation of 
cortical 
development 
Palmini II 
Lost to follow 
up 
*Intracranial EEG 
**EEG data recorded following right temporal lobectomy, essentially demonstrating contralateral temporal lobe seizures 
***Note that there was insufficient data to ascribe appropriate Engel outcome  
 
  
 
Page 29 of 30 Epilepsia
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
Table 2: Comparison of clinical characteristics between unilateral HS (n=201) vs bilateral 
HS cases (n=96).  
 
 Unilateral HS  
(n=201) 
Bilateral HS  
(n=96) 
P value 
History of febrile seizures 
     Yes 
     No 
     No data 
 
89 (44.3%) 
81 (40.3%) 
31 (15.4%) 
 
24 (25%) 
63 (65.6%) 
9 (9.4%) 
0.000236 
History of status epilepticus 
     Yes 
     No 
     No data 
 
23 (11.4%) 
69 (34.3%) 
109 (54.2%) 
 
26 (27.1%) 
64 (66.7%) 
6 (6.2%) 
< 0.00001 
Focal aware seizures* 
     Yes 
     No 
     No data 
 
84 (41.8%) 
106 (52.7%) 
11 (5.5%) 
 
21 (21.9%) 
71 (73.9%) 
4 (4.2%) 
0.002011 
Focal impaired awareness seizures 
     Yes 
     No 
     No data 
 
191 (95%) 
6 (3%) 
4 (2%) 
 
88 (91.7%) 
4 (4.2%) 
4 (4.2%) 
0.474705 
Focal to bilateral tonic-clonic seizures 
     Yes 
     No 
     No data 
 
131 (66.7%) 
59 (29.4%) 
8 (4%) 
 
64 (66.7%) 
28 (29.2%) 
4 (4.2%) 
0.993164 
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Table 3: Comparison of large case series of bilateral HS 
bHS: bilateral hippocampal sclerosis; uHS: unilateral hippocampal sclerosis; FC: febrile convulsion; SE: status epilepticus; FSE: febrile status epilepticus 
Publication Phenotype(s) Mean duration of 
epilepsy, years 
(range) 
History of FC History of SE or FSE History of 
encephalitis 
Other 
Ravat et al.
8
 35 patients with 
bHS 
15.7 (2-47) 19 (54.3%) history of 
FC 
 4 (11.4%) with history 
of encephalitic illness 
 
 
Malter et al.
9
 Total of 322 
patients: 31 with 
bHS, 291 with uHS 
11 (2-55) with bHS 
and 22 (0-65) with 
uHS (p=0.08, Fisher’s 
exact test) 
8 (26%) with bHS and 
69 (24%) with uHS had 
FC (p=0.024, Fisher’s 
exact test)  
3 (9.5%) of bHS and 1 (0.3%) of 
uHS had SE (p<0.001, Fisher’s 
exact test) 
8 (26%) with bHS and 
57 (20%) with uHS 
had encephalitis 
(p=0.44, Fisher’s exact 
test) 
3 (9.5%) with 
bHS and 9 (3%) 
with uHS had 
history of 
infantile brain 
damage (p=0.07, 
Fisher’s exact 
test) 
Van Paesschen et 
al.
10 
Total of 100 
patients: 7 with 
bHS, 41 with uHS, 5 
with anterior 
hippocampal 
atrophy, 47 with 
other findings 
28 (1-36) with bHS, 
20 (1-42) with uHS, 
15 (10-17) with 
anterior hippocampal 
atrophy (not 
significant) 
0 (0%) with bHS, 21 
(50%)  with uHS, and 4 
(80%) with anterior 
hippocampal atrophy 
had FC (p=0.00002, 
Fisher’s exact test) 
 3 (43%) with bHS, 5 
(12%) with uHS, and 0 
(0%) with anterior 
hippocampal atrophy 
had encephalitis (not 
significant) 
 
Vanli-Yavuz et al.
11
 Total of 124 
patients: 31 with 
bHS, 93 with uHS 
 20 (64.5%) with bHS 
and 60 (64.5%) with 
uHS had FC (not 
significant) 
 
 
 
10 with bHS (32.3%) and 9 
(9.7%) of uHS had history of SE 
(p=0.007, Fisher’s exact test) 
 
10 with bHS (32.3%) and 9 
(9.7%) with uHS had history of 
FSE with FSE (p=0.002, Fisher’s 
exact test) 
*3 patients had history of both 
SE and FSE 
 15 (48.4%) of 
bHS and 6 
(6.5%) with uHS 
had mental 
retardation 
(p<0.001, 
Pearson chi-
square) 
Current series 96 patients with 
bHS 
30.4 (1-79) 24 (25.0%) with history 
of FC 
26 (27.0%) with history of SE 10 (10.4%) with 
history of 
meningoencephalitis 
23 (24%) with 
known diagnosis 
of intellectual 
disability 
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